IP Verse

Cms Cameron Mckenna Nabarro Olswang patent opposition analysis

The comprehensive analysis of Cms Cameron Mckenna Nabarro Olswang opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Latest patent oppositions filed by Cms Cameron Mckenna Nabarro Olswang

Stay updated with the latest patent oppositions filed by Cms Cameron Mckenna Nabarro Olswang

Patent NumberTitleApplicantOpposition DateOpposition Company
EP4025192
Process For Producing A Tablet Comprising Glp-1 PeptidesNOVO NORDISK A/SSep 2, 2026CMS CAMERON MCKENNA NABARRO OLSWANG
EP3440518
Real Time Monitoring Of Product PurificationBOEHRINGER INGELHEIM RCV GMBH & CO KGAug 5, 2026CMS CAMERON MCKENNA NABARRO OLSWANG
EP3456192
Antibody Producing Non-Human MammalsMERUS N.V.Jun 3, 2026KYMAB
EP4074331
Compositions And Methods For Internalizing EnzymesREGENERON PHARMACEUTICALS, INC.Jun 3, 2026SANOFI
EP4349407
5-Methoxy-N,N-Dimethyltryptamine (5-Meo-Dmt) For Treating Major DepressionGH RESEARCH IRELAND LIMITEDJan 9, 2026STRAWMAN
EP3927338
Compositions Comprising 5-Methoxy-N,N-Dimethyltryptamine (5-Meo-Dmt) For Use In Treating Mental DisordersGH RESEARCH IRELAND LIMITEDJul 9, 2025STRAWMAN
EP3770258
Modulation Of Ube3A-Ats ExpressionIONIS PHARMACEUTICALS, INC.Apr 16, 2025CMS CAMERON MCKENNA NABARRO OLSWANG
EP3522732
Methods And Systems For Generating A Sterilized Human Milk ProductLACTALOGICS, INC.Jan 23, 2025STRAWMAN
EP3628319
Methods Of Treating Hepatic Encephalopathy Using RifaximinSALIX PHARMACEUTICALS, INC.Nov 14, 2024CMS CAMERON MCKENNA NABARRO OLSWANG
EP3927337
5-Methoxy-N,N-Dimethyltryptamine (5-Meo-Dmt) For Treating DepressionGH RESEARCH IRELAND LIMITEDNov 13, 2024STRAWMAN

Top clients of Cms Cameron Mckenna Nabarro Olswang

Top companies who are the clients of Cms Cameron Mckenna Nabarro Olswang

CompanyTotal
STRAWMAN14
CMS CAMERON MCKENNA NABARRO OLSWANG11
KYMAB9
TESLA GERMANY GMBH3
SANOFI2
SILENCE THERAPEUTICS2
NESTLE1
SNIPR BIOME1
POHLMAN1
BAE SYSTEMS1